H.C. Wainwright raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $125 from $123 and keeps a Buy rating on the shares. The company’s preliminary Q4 revenue beat estimates, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target raised to $145 from $140 at BofA
- Rhythm Pharmaceuticals: Raising Revenue Forecasts and Price Target on Strengthening BBS Growth and Clear aHO Catalyst Path
- Rhythm Pharmaceuticals Reports Strong Preliminary 2025 IMCIVREE Revenue
- Rhythm Pharmaceuticals Sees Q4 IMCIVREE product revenue $57M
- Rhythm Pharmaceuticals announces anticipated upcoming milestones